Status:
COMPLETED
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Chronic Hepatitis c
Eligibility:
All Genders
18+ years
Brief Summary
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment
Detailed Description
Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological...
Eligibility Criteria
Inclusion
- 18 years of age or older
- HCV patients treated with direct-acting antiviral treatment
- Patients with a prior treatment blood sample
- Patients with sustained virological response or virological relapse
Exclusion
- HIV or hepatitis B virus (HBV) coinfection
Key Trial Info
Start Date :
October 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2017
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT03348059
Start Date
October 1 2015
End Date
March 31 2017
Last Update
November 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Croix-Rousse Hospital, Hospices Civils de Lyon
Lyon, France, 69004